Ajanta Pharma today announced the launch of anti-dementia drug in the US market.
In a BSE filing, the company announced
"the launch of Memantine Hydrochloride tablets (anti-dementia drug) in the US market through its wholly-owned subsidiary Ajanta Pharma USA Inc".
Memantine Hydrochloride tablets is a bio-equivalent to generic version of Namenda.
"The company has launched Memantine Hydrochloride tablets in 5 mg and 10 mg strength to address different levels of treatment," it added.
The US Food and Drug Administration (USFDA) has granted final approvals for 10 abbreviated new drug applications (ANDAs) and 2 tentative approvals, it said, adding that an additional 14 ANDAs are under review.
Reference: http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/ajanta-pharma-launches-anti-dementia-drug-in-us/articleshow/52742080.cms
In a BSE filing, the company announced
"the launch of Memantine Hydrochloride tablets (anti-dementia drug) in the US market through its wholly-owned subsidiary Ajanta Pharma USA Inc".
Memantine Hydrochloride tablets is a bio-equivalent to generic version of Namenda.
"The company has launched Memantine Hydrochloride tablets in 5 mg and 10 mg strength to address different levels of treatment," it added.
The US Food and Drug Administration (USFDA) has granted final approvals for 10 abbreviated new drug applications (ANDAs) and 2 tentative approvals, it said, adding that an additional 14 ANDAs are under review.
Reference: http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/ajanta-pharma-launches-anti-dementia-drug-in-us/articleshow/52742080.cms
No comments:
Post a Comment